Table 2.
Patient Characteristics
| Control Cohort (n = 69) | NAFLD Cohort (n = 299) | P Value | |
|---|---|---|---|
| Female | 81% | 61 | .013 |
| Race | |||
| White | 72.5 | 84.9 | .02 |
| Black | 21.7 | 8.7 | |
| Asian | 2.9 | 2.0 | |
| Hispanic | 0.0 | 1.0 | |
| American Indian | 0.0 | 0.7 | |
| Multiple | 2.9 | 1.0 | |
| Unknown | 0 | 1.7 | |
| Age, y | 47.4 ± 12.6 | 50.5 ± 12.8 | .07 |
| BMI, kg/m2 | 37.4 ± 8.2 | 36.8 ± 8.1 | .58 |
| Diabetes | 17.4 | 47.8 | <.0001 |
| Hyperlipidemia | 46.4 | 34.4 | .07 |
| Hypertension | 43.5 | 32.4 | .17 |
| Fibrosis stage | |||
| 0 | 100.0 | 10.0 | <.0001 |
| 1 | — | 22.4 | |
| 2 | — | 35.8 | |
| 3 | — | 27.1 | |
| 4 | — | 4.7 | |
| NASH score | |||
| ≤3 | — | 1.7 | |
| 4 | — | 35.5 | |
| 5 | — | 36.5 | |
| 6 | — | 18.7 | |
| ≥7 | — | 7.7 | |
Values are % or mean ± SD.
BMI, body mass index; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.